News | April 24, 2025
Laurus Labs Q4 FY25 PAT up 208% to Rs. 234 Cr
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
The supply of these goods is set to commence within the first quarter of FY26
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Positions Curium as leading manufacturer of Lu-177 isotope
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Subscribe To Our Newsletter & Stay Updated
